Clinical Report: Mild Increases in C-Reactive Protein Levels Indicate Long-Term Outcomes in Heart Failure with Mildly Reduced Ejection Fraction

Overview

This study investigates the prognostic impact of C-reactive protein (CRP) levels in patients with heart failure with mildly reduced ejection fraction (HFmrEF). Elevated CRP levels were associated with long-term all-cause mortality and heart failure-related rehospitalization in this patient population.

Background

Heart failure (HF) is a significant cause of morbidity and mortality, with HFmrEF representing a notable subgroup that is often underrepresented in clinical studies. Understanding the role of inflammatory markers like CRP in this population is crucial, as systemic inflammation is a recognized feature of heart failure and may influence patient outcomes. This study aims to fill the evidence gap regarding the long-term prognostic value of CRP in HFmrEF patients.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

• HFmrEF patients represent about one quarter of the heart failure population.
• CRP is linked to adverse outcomes in heart failure, including mortality and rehospitalization.
• Elevated baseline CRP levels were found in patients with stable heart failure.
• CRP levels at 30 days post-admission were associated with all-cause mortality at 180 days in acute heart failure patients.
• The study was conducted at a single center and included patients hospitalized with HFmrEF from January 2016 to December 2022.

Clinical Implications

Monitoring CRP levels in patients with HFmrEF may provide valuable prognostic information regarding long-term outcomes. Clinicians should consider the inflammatory status of these patients when assessing their risk for adverse events.

Conclusion

The findings suggest that CRP levels may serve as a useful prognostic marker in patients with HFmrEF, highlighting the need for further research in this area.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. New Joint Scientific Statement on Ejection Fraction Released by Leading Heart Failure Organisations
9. Empagliflozin in Heart Failure with a Preserved Ejection Fraction | New England Journal of Medicine
10. Prevalence and Predictors of High Inflammatory Risk in Heart Failure Subtypes: Findings From the Global POSEIDON Study - PubMed